Distinct molecular signature of recurrent ovarian tumor cells isolated from the ascites of advanced-stage serous ovarian cancer patients

• DOI: 10.14343/jcscr.2014.2e1006
• Publication Date: 2014-12-08T11:36:23Z
• Authors: Ardian Latifi; Ruth Escalona; Michael A Quinn; Erik W Thompson; Jock K Findlay; Nuzhat Ahmed
• Keywords: Serous ovarian cancer; Ovarian tumor

Seventy percent of ovarian cancer patients die due to consecutive episodes recurrences resulting from the re-growth tumor cells resistant conventional chemotherapies.In an effort identify chemoresistance mechanisms, we compared expression genes in isolated ascites advanced-stage serous prior (chemonaive, CN) and after chemotherapy treatments (chemoresistant/recurrent, CR).A novel, recently published method was used for isolation CN CR patients.Illumina HT-12 platform assess differential (DEGs) between patients.The identification DEGs achieved by comparing genetic signatures versus samples a mean ratio (fold change) 2 P < 0.05.Validation selected performed quantitative Real Time Polymerase Chain Reaction (qRT-PCR).The dominant canonical pathways were determined Ingenuity Pathway Analysis.Gene analysis revealed 414 genes, with 179 up regulated 235 down group.There significant differences gene expressions encoding proteins involved stem cells, cell-cell adhesion, embryonic development, suppression, immune surveillance, retinoic acid energy metabolism patients.Pathway that changes cell cycle pathways, prominently those mitosis polo-like kinase (PLK1), G2/M DNA damage linked checkpoint regulation associated chemoresistance.This preliminary molecular profiling, on small number patient samples, suggests important discrimination derived patients.This type study larger cohort may have clinical implications development therapeutic strategies overcome patients.